GlassScriptPhysician profile
Kirkland Lau
NPI 1780670240
$10,221.81
in general payments reported to CMS, 2019-2025
31 companies · $1,791 in 2025
The $1,791 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,308 · 2020: $545 · 2021: $1,136 · 2022: $1,763 · 2023: $1,984 · 2024: $1,693 · 2025: $1,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,115 · Education: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,114.58 |
| Education | $353.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,188.76 | 2019-2025 | |
| Janssen Biotech, INC. | $1,071.93 | 2019-2025 | Tremfya, Remicade, Stelara |
| Sun Pharmaceutical Industries INC. | $882.61 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Pfizer INC. | $738.05 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $642.47 | 2019-2025 | Cabtreo, Jublia, Duobrii |
| Amgen INC. | $629.87 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $616.69 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $488.31 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $361.71 | 2019-2024 | Dupixent |
| Incyte Corporation | $325.97 | 2022-2025 | Opzelura |
| Genzyme Corporation | $320.70 | 2019-2025 | |
| Leo Pharma INC. | $285.01 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $280.62 | 2023-2025 | Sotyktu |
| Ucb, INC. | $246.45 | 2019-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $175.14 | 2019-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $134.32 | 2023-2025 | Zoryve |
| Organon LLC | $129.64 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $127.12 | 2022-2025 | Nemluvio |
| Biofrontera INC. | $107.59 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $90.93 | 2023-2024 | Vtama |
| Prugen, INC. Pharmaceuticals | $63.66 | 2020 | |
| Celgene Corporation | $62.04 | 2019 | |
| Journey Medical Corporation | $54.65 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.02 | 2023 | Spevigo, Cyltezo |
| Almirall LLC | $32.07 | 2020-2021 | |
| Vyne Pharmaceuticals INC. | $25.32 | 2021 | |
| Verrica Pharmaceuticals INC. | $23.48 | 2025 | Ycanth |
| Epi Health, LLC | $23.30 | 2022 | |
| Dermira, INC. | $18.96 | 2019 | |
| Promius Pharma LLC | $18.93 | 2019 | |
| Aclaris Therapeutics, INC. | $14.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirkland Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.